Reply to: Avoid valproate in patients with IARS2 mutations

Brain Dev. 2019 Jan;41(1):122. doi: 10.1016/j.braindev.2018.09.004. Epub 2018 Sep 22.

Authors

Yusuke Takezawa¹, Hiromi Fujie², Atsuo Kikuchi³, Shigeo Kure¹

Affiliations

¹ Department of Pediatrics, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
² Department of Pediatrics, Iwaki Kyoritsu General Hospital, 16 Kuzehara, Mimayamachi, Uchigo, Iwaki, Fukushima 973-8555, Japan.
³ Department of Pediatrics, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan. Electronic address: akikuchi-thk@umin.ac.jp.

PMID: 30253902
DOI: 10.1016/j.braindev.2018.09.004

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Mutation
Valproic Acid*

Substances

Valproic Acid